patent_id,patent_date,patent_title,patent_num_times_cited_by_us_patents,cpc_subclass_ids
12421223,2025-09-23,Compounds and compositions for treating conditions associated with NLRP activity,0,A61P|C07D
12419894,2025-09-23,Ribociclib tablet,0,A61K|A61P
12419889,2025-09-23,Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor,0,A61K|A61P
12410255,2025-09-09,Natriuretic peptide receptor 1 antibodies and methods of use,0,A61K|A61P|C07K|C12N
12404261,2025-09-02,Compounds and compositions for treating conditions associated with cGAS,0,A61K|A61P|C07D
12390468,2025-08-19,"Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide",0,A61K|A61P|C07B|C07D
12383601,2025-08-12,Chimeric antigen receptors and uses thereof,0,A61K|A61P|C07K|C12N
12383556,2025-08-12,Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor,0,A61K|A61P
12378222,2025-08-05,NLRP3 inflammasome inhibitors,0,A61K|A61P|C07D
12378206,2025-08-05,Heteroaryl butanoic acid derivatives,0,A61K|A61P|C07D
12371510,2025-07-29,Process for concentration of antibodies and therapeutic products thereof,0,A61K|B01D|C07K
12371481,2025-07-29,Methods for treating age-related macular degeneration,0,A61B|A61K|A61P|C07K
12365692,2025-07-22,"6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage",0,A61K|A61P|C07D
12365690,2025-07-22,"Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Cav1.2 activators",0,A61P|C07B|C07D
12358929,2025-07-15,NMDA receptor modulators and uses thereof,0,A61P|C07D
12358906,2025-07-15,Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors,0,A61K|C07D
12357630,2025-07-15,Ceritinib formulation,0,A61K|A61P
12344657,2025-07-01,"CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell",0,A61K|A61P|C07K|C12N
12344651,2025-07-01,CD19 and CD22 chimeric antigen receptors and uses thereof,0,A61K|C07K|C12N
12343344,2025-07-01,Pharmaceutical combination comprising TNO155 and ribociclib,0,A61K|A61P
12338290,2025-06-24,Regimens and methods of treating multiple sclerosis using ofatumumab,0,A61K|A61P|C07K
12338287,2025-06-24,Treatment of cancer using a CD33 chimeric antigen receptor,0,A61K|A61P|C07K
12338220,2025-06-24,Antiviral pyrazolopiridinone compounds,0,A61P|C07D
12331104,2025-06-17,Hepatitis B antibodies,0,A61K|A61P|C07K
12331060,2025-06-17,N-substituted tetrahydrothienopyridine derivatives and uses thereof,0,A61K|A61P|C07C|C07D|Y02A
12325870,2025-06-10,"Solubilized apyrases, methods and use",0,A61K|C12N|C12Y
12312353,2025-05-27,Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents,0,A61P|C07D
12296008,2025-05-13,Pharmaceutical products and stable liquid compositions of IL-17 antibodies,0,A61K|A61P|C07K|H04L
12286423,2025-04-29,"Antiviral 1,3-di-oxo-indene compounds",0,A61K|A61P|C07D|Y02A
12285422,2025-04-29,Uses of piperidinyl-indole derivatives,0,A61K|A61P|Y02A
12281125,2025-04-22,Rapamycin derivatives,0,A61K|C07D
12280041,2025-04-22,Compounds and compositions for inducing chondrogenesis,0,A61K|A61L|A61P|C07D|C12N|Y02A
12275795,2025-04-15,Binding molecules against BCMA and uses thereof,0,A61K|A61P|C07K|C12N
12258680,2025-03-25,Solid support,0,C07B|C07C|C07K|C40B|G01N
12257243,2025-03-25,5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage,0,A61K|A61P|C07D
12252535,2025-03-18,Antibody molecules to LAG-3 and uses thereof,0,A61K|A61P|C07K|G01N
12252482,2025-03-18,Pyrazolopyridine derivatives and uses thereof,0,A61K|A61P|C07D
12252479,2025-03-18,Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide,0,A61K|A61P|C07B|C07D
12252478,2025-03-18,Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide,0,A61K|A61P|C07B|C07D
12240884,2025-03-04,Methods for improving the efficacy and expansion of immune cells,0,A61K|A61P|C07K|C12N
12228571,2025-02-18,Cell-based assay for measuring drug product potency,0,A61K|C12N|C12Q|G01N
12226405,2025-02-18,Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use,0,A61K|A61P|C07B|C07D
12221481,2025-02-11,CD19 binding molecules and uses thereof,0,A61K|A61P|C07K|C12N
12215387,2025-02-04,Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment,0,A61K|A61P|C12Q
12214037,2025-02-04,Treatment of cancer using humanized anti-BCMA chimeric antigen receptor,0,A61K|A61P|C07H|C07K|C12N
12209144,2025-01-28,Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders,0,A61K|A61P|C07K
12209098,2025-01-28,N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2,0,A61K|A61P|C07B|C07D
12209096,2025-01-28,Compounds and compositions for inducing chondrogenesis,0,A61K|A61P|C07D
12208101,2025-01-28,"Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide",0,A61J|A61K|A61P|C07D
12208097,2025-01-28,Protein kinase C inhibitors for treatment of uveal melanoma,0,A61K|A61P
12201612,2025-01-21,Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use,1,A61K|A61P
12186278,2025-01-07,Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy,0,A61K|A61P
12180291,2024-12-31,Anti-CCR7 antibody drug conjugates,0,A61K|A61P|C07K
12172984,2024-12-24,Pyrazolopyridine derivatives and uses thereof,0,A61K|A61P|C07D
12171839,2024-12-24,Antibody drug conjugates for ablating hematopoietic stem cells,0,A61K|A61P|C07K
12168777,2024-12-17,Means and method for producing and purifying viral vectors,0,A61K|A61P|C07K|C12N|C12Y
12168012,2024-12-17,NLRP3 inflammasome inhibitors,0,A61K|A61P|C07D
12162922,2024-12-10,Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules,0,A61K|C07K|C12N|G01N|Y02A
12162890,2024-12-10,Heteroaromatic NMDA receptor modulators and uses thereof,0,A61K|A61P|C07D|C07F
12161648,2024-12-10,Covalent targeting of E3 ligases,0,A61K|A61P|C07D
12161624,2024-12-10,Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B,0,A61K|A61P|C07D
12157737,2024-12-03,Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof,0,A61K|A61P|C07D
12146187,2024-11-19,Methods of treating dry eye disease using TNF alpha antagonists,0,A61K|A61P|C07K|C12Q
12145909,2024-11-19,N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B,0,A61K|A61P|C07D
12139471,2024-11-12,NLRP3 inflammasome inhibitors,0,A61K|A61P|C07D
12138262,2024-11-12,"Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition",0,A61K|A61P|C07B|C07D|Y02P
12134611,2024-11-05,Compounds and compositions for treating conditions associated with NLRP activity,0,A61K|A61P|C07D
12129246,2024-10-29,Hydroquinazoline derivatives for the treatment of a disease or disorder,0,A61K|C07D
12128069,2024-10-29,Treatment of cancer using chimeric antigen receptor and protein kinase a blocker,0,A61K|C07K|C12N
12122761,2024-10-22,2-azaspiro[3.4]octane derivatives as M4 agonists,0,A61K|A61P|C07D
12103919,2024-10-01,"3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof",0,A61K|A61P|C07D
12091424,2024-09-17,Rapamycin derivatives,1,A61P|C07D|C07F
12090125,2024-09-17,Combination therapy,0,A61K|A61P
12084460,2024-09-10,Crystalline forms of a TLR7/TLR8 inhibitor,0,A61K|A61P|C07B|C07D
12084442,2024-09-10,Naphthyridinone derivatives for the treatment of a disease or disorder,0,A61K|A61P|C07D
12083101,2024-09-10,Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors,0,A61K|A61P|C07D
12083092,2024-09-10,"Antiviral 1,3-di-oxo-indene compounds",0,A61K|A61P|C07D|Y02A
12077580,2024-09-03,Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders,0,A61K|A61P|C07K
12077571,2024-09-03,Polyomavirus neutralizing antibodies,0,A61K|A61P|C07K|Y02A
12071441,2024-08-27,"10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza",0,A61P|C07D
12071402,2024-08-27,Immunosuppressant formulations,0,A61K|A61P|C07D
12065499,2024-08-20,Anti-CD40 antibodies for use in treatment of Sjögren's syndrome,0,A61K|A61P|C07K
12064434,2024-08-20,Ribociclib tablet,1,A61K|A61P
12054555,2024-08-06,Anti-BAFFR antibody formulations and methods of use thereof,0,A61K|C07K
12053470,2024-08-06,Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor,0,A61K|A61P
12049495,2024-07-30,Stable protein solution formulation containing high concentration of an anti-VEGF antibody,0,A61B|A61K|A61P|C07K
12049446,2024-07-30,"Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof",0,A61K|A61P|C07B|C07D
12048837,2024-07-30,Syringe,1,A61F|A61M|A61P|Y10T
12037583,2024-07-16,Compositions and methods for immunooncology,0,A61K|A61P|C07K|C12N|Y02A
12037378,2024-07-16,Variant CD58 domains and uses thereof,0,A61P|C07K
12036227,2024-07-16,Combination therapy,1,A61K|A61P
12031147,2024-07-09,Adeno-associated virus virions with variant capsids and methods of use thereof,0,A61P|C07K|C12N
12018024,2024-06-25,Compounds and compositions for the treatment of cryptosporidiosis,0,A61K|A61P|C07D|Y02A
12012636,2024-06-18,Pulmonary hypertension biomarker,0,A61P|C12Q|G01N
12012464,2024-06-18,Factor XI antibodies and methods of use,0,A61K|A61P|C07K
12012417,2024-06-18,N-substituted tetrahydrothienopyridine derivatives and uses thereof,0,A61K|A61P|C07C|C07D|Y02A
12011449,2024-06-18,Therapeutic combinations comprising a c-RAF inhibitor,1,A61K|A61P
12006354,2024-06-11,Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer,0,A61K|A61P|C07K|C12N
11999802,2024-06-04,Compositions and methods for selective protein degradation,0,A61K|C07D|C07K|C12N|C12Y|G01N
11999794,2024-06-04,Human mesothelin chimeric antigen receptors and uses thereof,0,A61K|A61P|C07K|C12N
11999786,2024-06-04,"Anti-CD48 antibodies, antibody drug conjugates, and uses thereof",0,A61K|A61P|C07K
11993586,2024-05-28,Crystalline forms of potassium channel modulators,0,A61P|C07B|C07D
11993582,2024-05-28,Crystalline forms of a LTA4H inhibitor,0,A61K|A61P|C07B|C07D
11987644,2024-05-21,"Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies",0,A61P|C07K|Y02A
11981731,2024-05-14,Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy,0,A61K|A61P|C07K|C12N
11975026,2024-05-07,CD19 and CD22 chimeric antigen receptors and uses thereof,0,A61K|C07K|C12N
11970525,2024-04-30,Treatment of cancer using GFR alpha-4 chimeric antigen receptor,0,A61K|A61P|C07K
11970497,2024-04-30,Tricyclic AKR1C3 dependent KARS inhibitors,0,A61K|A61P|C07D
11963999,2024-04-23,Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins,0,A61K|A61P|C07K
11958846,2024-04-16,Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors,1,A61K|C07D
11958805,2024-04-16,"Solid forms comprising an oxime ether compound, compositions and methods of use thereof",0,A61P|C07B|C07D
11952428,2024-04-09,BCMA chimeric antigen receptors and uses thereof,0,A61K|A61P|C07K|C12N
11952386,2024-04-09,N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2,0,A61K|A61P|C07B|C07D
11951190,2024-04-09,"Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer",2,A61K|A61P|C07B|C07D
11951101,2024-04-09,Methods of using factor B inhibitors,1,A61K|A61P
11945859,2024-04-02,Protein solution formulation containing high concentration of an anti-VEGF antibody,0,A61K|C07K
11944664,2024-04-02,Fibroblast growth factor-21-Fc fusion proteins,0,A61K|A61P|C07K
11944602,2024-04-02,Treatment of autoimmune disease in a patient receiving additionally a beta-blocker,0,A61K|A61P
11939397,2024-03-26,"ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies",0,A61K|A61P|C07K
11939389,2024-03-26,BCMA chimeric antigen receptors and uses thereof,0,A61K|A61P|C07K|C12N
11932681,2024-03-19,Hepatitis B antibodies,1,A61K|A61P|C07K
11931430,2024-03-19,Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer,2,A61K|A61P|C07B|C07D
11931363,2024-03-19,Triazolopyrimidine compounds and uses thereof,0,A61K|A61P|C07D
11930837,2024-03-19,Antibody-cytokine engrafted proteins and methods of use for immune related disorders,0,A23L|A23V|A61K|A61P|B02B|B02C|C07K
11919946,2024-03-05,Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy,0,C07K
11919911,2024-03-05,"Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators",1,A61P|C07B|C07D
11912978,2024-02-27,Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal,0,A61K|A61P|B03C|C07K|C12M|C12N
11912715,2024-02-27,Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections,0,A61K|A61P|C07D
11911371,2024-02-27,Pyridine and pyrazine derivative for the treatment of chronic bronchitis,0,A61K|A61P|C07D
11905283,2024-02-20,Compounds and compositions for inhibiting the activity of SHP2,0,A61P|C07D
11896614,2024-02-13,Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells,0,A61K|A61P|C07K|C12N|C12Y
11891401,2024-02-06,"Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide",0,A61K|A61P|C07B|C07C|C07D|Y02A
11878973,2024-01-23,Bicyclic compounds and their uses,2,A61P|C07B|C07D
11878060,2024-01-23,mRNA-mediated immunization methods,0,A61K|C07K
11878001,2024-01-23,Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use,1,A61K|A61P
11873307,2024-01-16,Manufacture of compounds and compositions for inhibiting the activity of SHP2,0,A61P|C07D|Y02P
11872249,2024-01-16,Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain,0,A61K|A61P|C07K|C12N
11866725,2024-01-09,Optimized lentiviral transfer vectors and uses thereof,0,C07K|C12N
11865167,2024-01-09,Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor,1,A61K|A61P|C07K
11865109,2024-01-09,"Formulations of (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide",0,A61K|A61P
11858981,2024-01-02,Humanization of rabbit antibodies using a universal antibody framework,0,A61K|A61P|C07K
11851666,2023-12-26,Multi-copy gene protein expression system,0,C07K|C12N|C12P
11851659,2023-12-26,Compositions and methods for immunooncology,0,A61K|A61P|C07K|C12N
11844864,2023-12-19,Method for preparing granules,0,A61K
11834508,2023-12-05,Method of treating structural and/or functional cardiac abnormalities by administering an anti-ActRII receptor antibody,0,A61K|A61P|C07K
11833215,2023-12-05,CKIT antibody drug conjugates,0,A61K|A61P|C07K
11833142,2023-12-05,"3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof",0,A61K|A61P|C07D
11827704,2023-11-28,Antibody molecules to PD-1 and uses thereof,1,A61K|A61P|C07K|G01N|Y02A
11820778,2023-11-21,2-azaspiro[3.4]octane derivatives as M4 agonists,0,A61K|A61P|C07D
11813306,2023-11-14,Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders,0,A61K|A61P|C07D|C07K
11807855,2023-11-07,Selection vectors and methods of selecting eukaryotic host cells,0,C07K|C12N
11807650,2023-11-07,NMDA receptor modulators and uses thereof,1,A61P|C07D
11802152,2023-10-31,Methods of treating FGF21-associated disorders,0,A61K|A61P|C07K
11801300,2023-10-31,Pharmaceutical products and stable liquid compositions of IL-17 antibodies,0,A61K|A61P|C07K|H04L
11787785,2023-10-17,Pyrazolopyridine derivatives and uses thereof,0,A61K|A61P|C07D
11786498,2023-10-17,Sacubitril calcium salts,0,A61K|A61P|C07B|C07C
11780927,2023-10-10,Anti-CD40 antibodies for use in prevention of graft rejection,0,A61K|A61P|C07K
11779649,2023-10-10,Antibodies to PMEL17 and conjugates thereof,0,A61K|A61P|C07K
11767370,2023-09-26,Process for concentration of antibodies and therapeutic products thereof,2,A61K|B01D|C07K
11760735,2023-09-19,Compounds and compositions for treating conditions associated with NLRP activity,0,A61K|A61P|C07C|C07D
11759436,2023-09-19,Dosage regimen of an S1P receptor modulator,0,A61B|A61K|A61P|G01N|G16H
11753416,2023-09-12,Compounds and compositions for inducing chondrogenesis,2,A61K|A61P|C07D
11752211,2023-09-12,Fatty acids and their use in conjugation to biomolecules,0,A61K|A61P|C07C|C12N
11752162,2023-09-12,Compounds and compositions for treating solid tumors by intratumoral administration,0,A61K|A61P|C07K
11747346,2023-09-05,Biomarkers predictive of cytokine release syndrome,1,A61K|A61P|C07K|C12Q|G01N
11747319,2023-09-05,Computer method and system for deriving cell-to-cell spatial proximities,0,A61P|G01N|G06T|G16H
11738028,2023-08-29,Therapeutic regimen,0,A61K|A61P|Y02A
11726092,2023-08-15,Method of scoring a sample comprising tumor tissue,0,A61P|G01N|G06T
11725246,2023-08-15,Methods of treating ophthalmic disorders,1,A61P|C07K|C12Q
11723901,2023-08-15,Uses of piperidinyl-indole derivatives,2,A61K|A61P|Y02A
11718631,2023-08-08,Sulphonamides and compositions thereof for treating conditions associated with NLRP activity,0,A61P|C07C|C07D
11708412,2023-07-25,Methods for treating hematologic cancers,1,A61K|A61N|C07K
11708366,2023-07-25,Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof,1,A61K|A61P|C07D
11702409,2023-07-18,Pyrazolyl derivatives useful as anti-cancer agents,0,A61P|C07B|C07D
11692046,2023-07-04,FGF21 mimetic antibodies and uses thereof,0,A61K|A61P|C07K
11685776,2023-06-27,Engineered heterodimeric proteins,0,C07K
11673868,2023-06-13,Amino pyrimidine derivatives,0,A61K|A61P|C07D|Y02P
11672799,2023-06-13,"1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions",0,A61K|A61P|C07D
11672782,2023-06-13,Carboxamide derivatives,0,A61K|A61P|C07D
11667691,2023-06-06,Treatment of cancer using chimeric CD3 receptor proteins,0,C07K
11667613,2023-06-06,Antiviral pyrazolopyridinone compounds,0,A61P|C07D
11654144,2023-05-23,"Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts",0,A61K|A61P|C07B|C07D|C07K
11648253,2023-05-16,Thienopyrimidinone NMDA receptor modulators and uses thereof,0,A61K|A61P|C07D
11642315,2023-05-09,Method for preparing a pharmaceutical product,0,A61J|A61K
11639378,2023-05-02,Polyomavirus neutralizing antibodies,1,A61K|A61P|C07K|Y02A
11634497,2023-04-25,Anti-CCR7 antibody drug conjugates,2,A61K|A61P|C07K
11629149,2023-04-18,"10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza",2,A61P|C07D
11629124,2023-04-18,"Solid forms comprising an oxime ether compound, compositions and methods of use thereof",1,A61K|C07B|C07D
11628137,2023-04-18,Parenteral formulation comprising siponimod,0,A61K
11613543,2023-03-28,"Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors",0,A61K|A61P|C07D
11612659,2023-03-28,Anti-CD40 antibody formulation delivery device,0,A61K|A61P|C07K
11608382,2023-03-21,BCMA chimeric antigen receptors and uses thereof,3,A61K|A61P|C07K|C12N
11597733,2023-03-07,Compounds and compositions for the treatment of parasitic diseases,0,A61K|A61P|C07B|C07C|C07D|Y02A
11597706,2023-03-07,Compounds and compositions for treating conditions associated with NLRP activity,0,A61K|A61P|C07C|C07D
11596695,2023-03-07,Specific sites for modifying antibodies to make immunoconjugates,0,A61K|A61P|C07K
11591404,2023-02-28,Treatment of cancer using a CD123 chimeric antigen receptor,0,A61K|A61P|C07K|C12N
11590158,2023-02-28,Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same,0,A61K|A61P|C07B|C07C|C07D
11578130,2023-02-14,Regulatable chimeric antigen receptor,0,A61K|A61P|C07K|C12N|C12Y
11578123,2023-02-14,Stable and soluble antibodies inhibiting TNFα,0,A61P|C07K
11566022,2023-01-31,"3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof",1,A61K|A61P|C07D
11549099,2023-01-10,Cell secreted minibodies and uses thereof,0,A61K|C07K|C12N
11548897,2023-01-10,Crystalline forms of a triazolopyrimidine compound,0,A61K|A61P|C07B|C07D
11548865,2023-01-10,2-azaspiro[3.4]octane derivatives as M4 agonists,1,A61K|A61P|C07D
11542488,2023-01-03,Sortase synthesized chimeric antigen receptors,1,C07K|C12N
11541056,2023-01-03,"3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives",1,A61K|A61P|C07D
11535662,2022-12-27,CD28 compositions and methods for chimeric antigen receptor therapy,0,A61K|A61P|C07K|C12N
11534491,2022-12-27,Methods of treating ankylosing spondylitis using IL-17 antagonists,0,A61K|A61P|C07K
11534490,2022-12-27,Methods of treating psoriasis using IL-17 antagonists,0,A61K|A61P|C07K
11530413,2022-12-20,Compositions and methods to treat cancer,2,A61K|C12N|C12Q|C12Y|G01N
11530261,2022-12-20,Compositions and methods for antibodies targeting BMP6,0,A61K|A61P|C07K
11530213,2022-12-20,Naphthyridinone derivatives and their use in the treatment of arrhythmia,0,A61K|A61P|C07B|C07D|C07F
11524998,2022-12-13,"Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules",1,A61K|A61P|C07K
11524070,2022-12-13,Manufacture of surfactant-containing compositions with enhanced stability,0,A61K|B01D|C12N
11512335,2022-11-29,Vertebrate cells and methods for recombinantly expressing a polypeptide of interest,0,C12N|C12P|C12Y|G01N
11510912,2022-11-29,Compounds and compositions for inducing chondrogenesis,1,A61K|A61L|A61P|C07D|C12N|Y02A
11505541,2022-11-22,Protein kinase C inhibitors and methods of their use,1,A61K|A61P|C07D
11504333,2022-11-22,Pharmaceutical composition,0,A61K|A61P
11492409,2022-11-08,Binding molecules against BCMA and uses thereof,2,A61K|A61P|C07K|C12N
11492402,2022-11-08,TREM2 stabilizing antibodies,0,A61K|A61P|C07K|C12N
11485742,2022-11-01,2-azaspiro[3.4]octane derivatives as M4 agonists,1,A61K|A61P|C07D
11480570,2022-10-25,Method of deriving a value for percent biomarker positivity for selected cells present in a field of view,0,C12Q|G01N
11478480,2022-10-25,Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile,1,A61K|A61P
11473083,2022-10-18,Compositions and methods for decreasing tau expression,0,A61K|A61P|C12N
11466271,2022-10-11,Compositions and methods for the treatment of hemoglobinopathies,0,A61K|A61P|C12N
11466048,2022-10-11,"3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA",3,C07F|C07H|C07K
11466023,2022-10-11,"Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof",0,A61K|A61P|C07D
11464871,2022-10-11,Methods and systems for polymer precipitation and generation of particles,0,A61K
11459390,2022-10-04,Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor,0,A61K|A61P|C07K|C12N
11458138,2022-10-04,6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors,0,A61K|A61P|C07D|C12N
11453679,2022-09-27,"Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Cav1.2 activators",0,A61P|C07D
11453677,2022-09-27,Tricyclic compounds useful to treat orthomyxovirus infections,2,A61P|C07D
11453651,2022-09-27,Heteroaryl butanoic acid derivatives,0,A61K|A61P|C07D
11447460,2022-09-20,Compounds and compositions for treating conditions associated with NLRP activity,0,A61P|C07C|C07D
11434269,2022-09-06,Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6),0,A61K|A61P|C07K|G01N
11434200,2022-09-06,"Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof",2,A61K|A61P|C07B|C07D
11433132,2022-09-06,Polyomavirus neutralizing antibodies,2,A61K|A61P|C07K|Y02A
11430111,2022-08-30,Computer processes behind an enhanced version of aqua,0,G01N|G06T|G06V|G16B
11427586,2022-08-30,"1,2,4-oxadiazole derivatives as liver X receptor agonists",0,A61P|C07B|C07D
11426381,2022-08-30,Lipoic acid choline ester compositions and methods of use,0,A61K|A61P
11426375,2022-08-30,Substituted bisphenyl butanoic ester derivatives as NEP inhibitors,0,A61K|A61P|C07C|C07D
11420970,2022-08-23,Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents,1,A61P|C07D
11420933,2022-08-23,Lipids and lipid compositions for the delivery of active agents,0,A61K|C07C|C07D|C12N
11419870,2022-08-23,Intermittent dosing of MDM2 inhibitor,1,A61K|A61P
11414411,2022-08-16,Chemical process for manufacturing monobactam antibiotic and intermediates thereof,0,A61P|C07C|C07D|Y02P
11413340,2022-08-16,Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy,1,A61K|A61P
11413284,2022-08-16,Protein kinase C inhibitors for treatment of uveal melanoma,1,A61K|A61P
11407735,2022-08-09,Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide,2,A61K|A61P|C07B|C07D
11406627,2022-08-09,Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers,0,A61K|A61P
11401259,2022-08-02,1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2,0,A61P|C07D
11389541,2022-07-19,Sustained delivery of angiopoetin-like 3 polypeptides,0,A61K|A61P|C07K
11384078,2022-07-12,"5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases",0,A61K|A61P|C07D|Y02A
11382905,2022-07-12,Immunomodulation by IAP inhibitors,0,A61K|A61P|C12N
11377656,2022-07-05,Chemically modified messenger RNA's,0,C07H|C12N
11370820,2022-06-28,Peptides and compositions for treatment of joint damage,0,A61K|A61P|C07K|C12N|C12Q|G01N|Y02A
11370763,2022-06-28,Compounds and compositions for treating conditions associated with NLRP activity,0,A61K|A61P|C07C|C07D
11369603,2022-06-28,Use of a H3R inverse agonist for the treatment of shift work disorder,0,A61K|A61P
11359241,2022-06-14,Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment,0,A61K|A61P|C12Q
11357864,2022-06-14,Antibody drug conjugates for ablating hematopoietic stem cells,0,A61K|A61P|C07K
11357851,2022-06-14,"Uses of myostatin antagonists, combinations containing them and uses thereof",0,A61K|A61P
11351253,2022-06-07,Methods of treating palmoplantar pustular psoriasis (PPP) using IL-17 antibody,0,A61K|A61P|C07K
11351223,2022-06-07,Methods and compositions for treatment of cartilage damage and arthritis,0,A61K|A61P
11344620,2022-05-31,Combination therapies,4,A61K|A61P|C07K
11344540,2022-05-31,Methods for treating liver disorders using FXR agonists,0,A61K|A61P
11339209,2022-05-24,"Compositions, methods, and therapeutic uses related to fusogenic protein minion",0,A61K|A61P|C07K|C12N|Y02A
11339136,2022-05-24,Compounds and compositions for treating conditions associated with NLRP activity,0,A61K|A61P|C07C|C07D
11312783,2022-04-26,Antibody molecules to CD73 and uses thereof,1,A61K|A61P|C07K|G01N
11312766,2022-04-26,Antibodies against growth differentiation factor 15 and uses thereof,0,A61K|A61P|C07K
11311525,2022-04-26,Use of alpha 7 nicotinic acetylcholine receptor agonists,0,A61K
11311400,2022-04-26,Methods for making conjugates from disulfide-containing proteins,0,A61C|A61F|A61K
11304907,2022-04-19,Pharmaceutical compositions containing a DGAT1 inhibitor,0,A61K|A61P
11292833,2022-04-05,Selective reduction of cysteine residues in IL-17 antibodies,0,C07K
11291661,2022-04-05,Pharmaceutical composition,0,A61K|A61P
11278618,2022-03-22,Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients,0,A61K|A61P|C07K
11274080,2022-03-15,Diamino pyridine derivatives,0,A61K|A61P|C07D
11266653,2022-03-08,Combination therapy,6,A61K|A61P
11254653,2022-02-22,NLRP3 inflammasome inhibitors,11,A61K|A61P|C07D
11249066,2022-02-15,Computer method and system for deriving cell-to-cell spatial proximities,0,A61P|G01N|G06T|G16H
11242551,2022-02-08,Eukaryotic cells and methods for recombinantly expressing a product of interest,0,C07K|C12N|C12P|C12Q
11241482,2022-02-08,Mesenchymal stem cell differentiation,0,A61K|A61P|C07K
11236366,2022-02-01,Production of squalene from hyper-producing yeasts,0,A61P|C12P
11236159,2022-02-01,Methods of treating FGF21-associated disorders,0,A61K|A61P|C07K
11234982,2022-02-01,Methods for treating ocular surface pain,0,A61K|A61P
11234977,2022-02-01,Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals,0,A01N|A61K|A61P|C07D
11230718,2022-01-25,Optimized expression cassette for expressing a polypeptide with high yield,0,C07K|C12N
11229648,2022-01-25,"1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions",0,A61K|A61P|C07D
11229643,2022-01-25,Combinations of FGFR4 inhibitors and bile acid sequestrants,0,A61K|A61P
11229634,2022-01-25,Methods for treating gastrointestinal disorders using FXR agonists,0,A61K|A61P
11220681,2022-01-11,Enzymatic reaction medium containing surfactant,0,C11D|C12N|C12P
11208399,2021-12-28,NLRP3 inflammasome inhibitors,2,A61K|A61P|C07D
11207325,2021-12-28,Triazolopyrimidine compounds and uses thereof,1,A61K|A61P|C07D
11207313,2021-12-28,Pharmaceutical composition,0,A61K|A61P
11203631,2021-12-21,Eukaryotic cells and methods for recombinantly expressing a product of interest,0,C07K|C12N
11203620,2021-12-21,Constitutive yeast LLP promotor-based expression systems,0,C07K|C12N
11203595,2021-12-21,Aza-indazole compounds for use in tendon and/or ligament injuries,0,A61K|A61P|C07D
11197826,2021-12-14,Oil-in-water emulsions including retinoic acid,0,A61K|A61M|A61P
11192877,2021-12-07,"3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof",3,A61P|C07D
11185635,2021-11-30,Syringe,2,A61F|A61M|A61P|Y10T
11185537,2021-11-30,"3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof",3,A61K|A61P|C07D
11180546,2021-11-23,TGFbeta 2 antibodies,0,A61K|A61P|C07K
11180460,2021-11-23,Amino pyrimidine derivatives,1,A61K|A61P|C07D|Y02P
11179521,2021-11-23,Syringe,2,A61F|A61M|A61P|Y10T
11179442,2021-11-23,Peptides and compositions for treatment of joint damage,1,A61K|A61P|C07K|C12N
11179413,2021-11-23,Methods of treatment of cancer with reduced UBB expression,0,A61K|A61P|C12N|C12Q|G01N
11179365,2021-11-23,Pharmaceutical combination comprising LSZ102 and ribociclib,0,A61K|A61P
11179364,2021-11-23,Licofligozin for the treatment of non-alcoholic steatohepatitis,0,A61K|A61P
11174494,2021-11-16,Expression vector system comprising two selection markers,1,C12N|C12P|C12Y
11168147,2021-11-09,Factor XI antibodies and methods of use,1,A61K|A61P|C07K
11162065,2021-11-02,Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal,8,A61K|A61P|B03C|C07K|C12M|C12N
11161909,2021-11-02,Regimens and methods of treating multiple sclerosis using ofatumumab,1,A61K|A61P|C07K
11161907,2021-11-02,Car-expressing cells against multiple tumor antigens and uses thereof,5,A61K|A61P|C07K|C12N
11161894,2021-11-02,Polyomavirus neutralizing antibodies,2,A61K|A61P|C07K|Y02A
11160804,2021-11-02,Pharmaceutical dosage forms,0,A61K|A61P
11160797,2021-11-02,Pyridinone derivatives and their use as selective ALK-2 inhibitors,0,A61K|A61P|C07D
11155620,2021-10-26,Method of detecting TIM-3 using antibody molecules to TIM-3,5,A61K|A61P|C07K|G01N|Y02A
11149076,2021-10-19,"CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell",5,A61K|A61P|C07K|C12N
11147925,2021-10-19,Syringe,1,A61F|A61M|A61P|Y10T
11141376,2021-10-12,Circulation of components during microfluidization and/or homogenization of emulsions,0,A61K|A61P|B01F
11136366,2021-10-05,Methods of treating immune related disorders using antibody-cytokine engrafted compositions,0,A61K|A61P|C07K
11135239,2021-10-05,Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same,0,A61K|A61P|C07B|C07C|C07D
11135192,2021-10-05,Inhibitors for treating diseases characterized by atrial enlargement or remodeling,0,A61K|A61P
11129874,2021-09-28,Nucleic acids encoding FGF21-Fc fusion proteins,1,A61K|A61P|C07K
11124578,2021-09-21,Method of treating transplant rejection with silent Fc variants of anti-CD40 antibodies,2,A61K|A61P|C07K
11123348,2021-09-21,Compounds and compositions for the treatment of parasitic diseases,0,A61K|A61P|C07D|C07F|Y02A
11122825,2021-09-21,Antibody-cytokine engrafted proteins and methods of use for immune related disorders,0,A23L|A23V|A61K|A61P|B02B|B02C|C07K
11111293,2021-09-07,IL-18 binding molecules,0,C07K|C12P|G01N
11111283,2021-09-07,Peptides and compositions for treatment of joint damage,1,A61K|A61P|C07K|C12N|C12Q|G01N|Y02A
11110226,2021-09-07,Syringe,2,A61F|A61M|A61P|Y10T
11110150,2021-09-07,Complexes of IL-15 and IL-15Ralpha and uses thereof,1,A61K|A61P|C07K|C12N
11110083,2021-09-07,Methods for treating liver disorders using FXR agonists,0,A61K|A61P
11103644,2021-08-31,Syringe,2,A61F|A61M|A61P|Y10T
11103469,2021-08-31,Combination therapy,1,A61K|A61P
11098110,2021-08-24,Methods for treating ocular diseases with brolucizumab,5,A61B|A61K|A61P|C07K
11098077,2021-08-24,Locked nucleic acid cyclic dinucleotide compounds and uses thereof,0,A61K|A61P|C07H|C12N
11098051,2021-08-24,Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections,3,A61K|A61P|C07D
11096947,2021-08-24,Combination products with tyrosine kinase inhibitors and their use,0,A61K|A61P|C07D
11096916,2021-08-24,Use of nicotinic acetylcholine receptor alpha 7 activators,0,A61K|A61P
11091499,2021-08-17,Compounds and compositions for inducing chondrogenesis,3,A61K|A61P|C07D
11091489,2021-08-17,Crystalline forms of a triazolopyrimidine compound,0,A61K|A61P|C07B|C07D
11084880,2021-08-10,Anti-BCMA chimeric antigen receptor,8,A61K|A61P|C07H|C07K|C12N
11078191,2021-08-03,1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer,1,A61K|A61P|C07D|C07K
11077186,2021-08-03,Methods for preparing squalene,0,A61K|A61P|B01D|B01L|C07C|C12N
11072610,2021-07-27,Antiviral pyridopyrazinedione compounds,0,A61P|C07D
11066469,2021-07-20,Natriuretic peptide receptor 1 antibodies and methods of use,0,A61K|A61P|C07K|C12N
11066369,2021-07-20,N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease,0,A61K|A61P|C07D
11059804,2021-07-13,Protein kinase C inhibitors and methods of their use,2,A61K|A61P|C07D
11058677,2021-07-13,LFA-1 inhibitor formulations,0,A61K|A61P
11058667,2021-07-13,Sacubitril-valsartan dosage regimen for treating heart failure,0,A61K|A61P
11052069,2021-07-06,Regimes of FXR agonists,0,A61K|A61P
11046757,2021-06-29,Solubility optimization of immunobinders,0,A61P|C07K
11045463,2021-06-29,Methods of enhancing immune response,0,A61K|A61P
11028177,2021-06-08,Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells,1,A61K|A61P|C07K
11028143,2021-06-08,Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules,5,A61K|C07K|C12N|G01N|Y02A
11026993,2021-06-08,Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders,0,A61K|A61P|C07D|C07K
11026976,2021-06-08,Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain,2,A61K|A61P|C07K|C12N
11021446,2021-06-01,Compositions and methods for modulating farnesoid X receptors,0,A61K|A61P|C07D
11013696,2021-05-25,Lipids and lipid compositions for the delivery of active agents,1,A61K|C07C|C07D|C12N
11008570,2021-05-18,3′ end caps for RNAi agents for use in RNA interference,0,A61P|C07C|C07D|C12N
11001628,2021-05-11,Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer,0,A61K|A61P|C07K
10993940,2021-05-04,Methods of enhancing immune response,0,A61K|A61P
10982000,2021-04-20,Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody,1,A61K|A61P|C07K
10981990,2021-04-20,Antibody molecules to TIM-3 and uses thereof,10,A61K|A61P|C07K|G01N|Y02A
10975145,2021-04-13,Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event,0,A61K|A61P|C07K
10975120,2021-04-13,Site-specific chemoenzymatic protein modifications,0,A61K|A61P|C07C|C07D|C07K
10975114,2021-04-13,Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof,0,A61K|A61P|C07H
10975080,2021-04-13,Compounds and compositions for inhibiting the activity of SHP2,1,A61K|A61P|C07D
10975078,2021-04-13,Fused indazole pyridone compounds as antivirals,0,A61K|A61P|C07D
10973899,2021-04-13,Flavivirus replicons,2,A61K|A61P|C12N|Y02A
10973829,2021-04-13,Therapeutic uses of a C-RAF inhibitor,3,A61K|A61P
10973826,2021-04-13,Antibody conjugates comprising toll-like receptor agonist,4,A61K|A61P|C07D|C07H|C07K
10968272,2021-04-06,Methods of treating a crystal induced arthropathy using IL-1beta antibodies,0,A61K|A61P|C07K
10968235,2021-04-06,N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2,3,A61K|A61P|C07B|C07D
10966978,2021-04-06,Dose and regimen for HDM2-p53 interaction inhibitors,1,A61K|A61P
10960087,2021-03-30,Compositions and methods for treatment of diabetic retinopathy,0,A61F|A61K|A61P|C07K|G01N|Y02A
10954493,2021-03-23,Decreasing potential iatrogenic risks associated with influenza vaccines,0,A61K|A61P|C12N|C12Q|G01N|Y02A
10954233,2021-03-23,Compounds and compositions as inhibitors of endosomal toll-like receptors,0,A61K|A61P|C07D
10952989,2021-03-23,SGLT1/2 inhibitor LIK066 for treating obesity,0,A61K|A61P
10947218,2021-03-16,Aminopyridine derivatives and their use as selective ALK-2 inhibitors,2,A61P|C07D|Y02A
10935540,2021-03-02,GDF-15 as a haematological toxicity biomarker,1,A61K|A61P|C12Q|G01N
10934285,2021-03-02,Compounds and compositions for inhibiting the activity of SHP2,4,A61P|C07D
10934273,2021-03-02,"Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide",0,A61P|C07B|C07D
10933064,2021-03-02,"Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and new salts",1,A61K|A61P|C07B|C07D|C07K
10927184,2021-02-23,Treatment of cancer using humanized anti-CD19 chimeric antigen receptor,5,A61K|A61P|C07K|C12N
10919887,2021-02-16,Salts and solid forms of a monobactam antibiotic,0,A61P|C07B|C07D|Y02A
10906930,2021-02-02,Compositions and methods for activating “stimulator of interferon gene”-dependent signalling,2,A61K|A61P|C07H
10906867,2021-02-02,Lipids and lipid compositions for the delivery of active agents,37,A61K|C07C|C07D|C12N
